Literature DB >> 15456750

A polymorphism in thrombospondin-1 associated with familial premature coronary artery disease alters Ca2+ binding.

Blue-leaf A Hannah1, Tina M Misenheimer, Michelle M Pranghofer, Deane F Mosher.   

Abstract

A single nucleotide polymorphism that results in substitution at residue 700 of a serine (Ser-700) for an asparagine (Asn-700) in thrombospondin-1 is associated with familial premature coronary artery disease. The polymorphism is located in the first of 13 Ca2+ -binding motifs, within a consensus sequence in which Asn-700 likely coordinates Ca2+. Equilibrium dialysis of constructs comprised of the adjoining epidermal growth factor-like module and the Ca2+ -binding region (E3Ca) demonstrated that E3Ca Ser-700 binds significantly less Ca2+ than E3Ca Asn-700 at low [Ca2+]. The hypothesis that this difference is due to loss of a binding site in Ser-700 protein was tested with truncations of E3Ca containing four (Tr4), three (Tr3), two (Tr2), or one (Tr1) N-terminal Ca2+ -binding motifs. The Ser-700 truncation constructs bound 1 fewer Ca2+ than matching Asn-700 constructs and exhibited decreased binding affinities. Intrinsic fluorescence of a tryptophan at residue 698 (Trp-698) in the most N-terminal motif was cooperatively quenched by the addition of Ca2+ to Asn-700 Tr2, Tr3, and Tr4 constructs. In Ser-700 constructs, quenching of Trp-698 was incomplete in the Tr2 and Tr3 constructs and complete only in the Tr4 construct. Ca2+ -induced quenching of Ser-700 constructs required higher [Ca2+] and was slower as shown in stopped-flow experiments than quenching of Asn-700 constructs. Such differences were not found with Tb3+, which quenched the fluorescence of Asn-700 and Ser-700 constructs equivalently. Thus, the Ser-700 polymorphism alters a rapidly filled, high affinity Ca2+ -binding site in the first Ca2+ -binding motif. Slower Ca2+ binding to adjoining motifs partly compensates for the change.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456750     DOI: 10.1074/jbc.M409632200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Biophysical characterization of the signature domains of thrombospondin-4 and thrombospondin-2.

Authors:  Tina M Misenheimer; Deane F Mosher
Journal:  J Biol Chem       Date:  2005-10-24       Impact factor: 5.157

Review 2.  Structures of thrombospondins.

Authors:  C B Carlson; J Lawler; D F Mosher
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

3.  The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size.

Authors:  Jeffrey I Zwicker; Flora Peyvandi; Roberta Palla; Rossana Lombardi; Maria Teresa Canciani; Andrea Cairo; Diego Ardissino; Luisa Bernardinelli; Kenneth A Bauer; Jack Lawler; Pier Mannucci
Journal:  Blood       Date:  2006-05-09       Impact factor: 22.113

4.  Polymorphism in THBS1 gene is associated with post-refractive surgery chronic ocular surface inflammation.

Authors:  Laura Contreras-Ruiz; Denise S Ryan; Rose K Sia; Kraig S Bower; Darlene A Dartt; Sharmila Masli
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

5.  Structure of the calcium-rich signature domain of human thrombospondin-2.

Authors:  C Britt Carlson; Douglas A Bernstein; Douglas S Annis; Tina M Misenheimer; Blue-leaf A Hannah; Deane F Mosher; James L Keck
Journal:  Nat Struct Mol Biol       Date:  2005-09-25       Impact factor: 15.369

6.  Pancreatic β-cell protection from inflammatory stress by the endoplasmic reticulum proteins thrombospondin 1 and mesencephalic astrocyte-derived neutrotrophic factor (MANF).

Authors:  Daniel A Cunha; Monia Cito; Fabio Arturo Grieco; Cristina Cosentino; Tatiana Danilova; Laurence Ladrière; Maria Lindahl; Andrii Domanskyi; Marco Bugliani; Piero Marchetti; Décio L Eizirik; Miriam Cnop
Journal:  J Biol Chem       Date:  2017-07-11       Impact factor: 5.157

7.  Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function.

Authors:  Elzbieta Pluskota; Olga I Stenina; Irene Krukovets; Dorota Szpak; Eric J Topol; Edward F Plow
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

8.  Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain.

Authors:  Barbara Margosio; Marco Rusnati; Katiuscia Bonezzi; Blue-Leaf A Cordes; Douglas S Annis; Chiara Urbinati; Raffaella Giavazzi; Marco Presta; Domenico Ribatti; Deane F Mosher; Giulia Taraboletti
Journal:  Int J Biochem Cell Biol       Date:  2007-10-09       Impact factor: 5.085

9.  Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.

Authors:  Giorgio Colombo; Barbara Margosio; Laura Ragona; Marco Neves; Silvia Bonifacio; Douglas S Annis; Matteo Stravalaci; Simona Tomaselli; Raffaella Giavazzi; Marco Rusnati; Marco Presta; Lucia Zetta; Deane F Mosher; Domenico Ribatti; Marco Gobbi; Giulia Taraboletti
Journal:  J Biol Chem       Date:  2010-01-07       Impact factor: 5.157

10.  Interactions among the epidermal growth factor-like modules of thrombospondin-1.

Authors:  Yuanyuan Liu; Douglas S Annis; Deane F Mosher
Journal:  J Biol Chem       Date:  2009-06-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.